VTRS vs. TMO VTRS has lower growth assets with fairly consistent cashflows. TMO is into tools and diagnostics. 75% of TMO's business is consumables. It's benefitting significantly from Covid, and this should continue. They blew away estimates, and so you pay a bit more for it.
Brand new company from the merger if Mylan and Upjohn. Trades at 6x earnings and nobody has covered this. This stock will trade at 10-11x earnings, nearly doubling. This is his most compelling top pick today. The company is already generating profits and cash flow. They make Xoloft, Viagra, Lipotor mostly from Upjohn. They also have a pipeline of new drugs company. Seasoned managers. (Analysts’ price target is $22.43)
Brand new company from the merger if Mylan and Upjohn. Trades at 6x earnings and nobody has covered this. This stock will trade at 10-11x earnings, nearly doubling. This is his most compelling top pick today. The company is already generating profits and cash flow. They make Xoloft, Viagra, Lipotor mostly from Upjohn. They also have a pipeline of new drugs company. Seasoned managers. (Analysts’ price target is $22.43)
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q
In the last year, there was no coverage of Viatris published on Stockchase.
Viatris was recommended as a Top Pick by Paul MacDonald on 2021-02-11. Read the latest stock experts ratings for Viatris.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.
On 2021-04-16, Viatris (VTRS-Q) stock closed at a price of $13.4.
